Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 517-525

  Matsumura, Y ^a   Gotoh, M ^b   Muro, K ^b   Yamada, Y ^b   Shirao, K ^b   Shimada, Y ^b   Okuwa, M ^c   Matsumoto, S ^c   Miyata, Y ^c   Ohkura, H ^c   Chin, K ^d   Baba, S ^d   Yamao, T ^d   Kannami, A ^e   Takamatsu, Y ^e   Ito, K ^e   Takahashi, K ^e  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Doxorubicin; Drug delivery system; GAH; Immunoliposome; MCC 465; Pharmacokinetics

Indexed keywords

7 DEOXYDOXORUBICINOL; CHLORPHENIRAMINE MALEATE; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MACROGOL; MCC 465; MONOCLONAL ANTIBODY; PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOXICITY; DRUG URINE LEVEL; ERYTHEMA; FEVER; FLUSHING; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEAT SENSATION; HUMAN; HYPERTENSION; LEUKOPENIA; LOW BACK PAIN; MALAISE; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECURRENT CANCER; RIGOR; SHIVERING; SIDE EFFECT; SKIN TOXICITY; STOMACH CANCER; STOMATITIS; TACHYCARDIA; TASTE DISORDER; THORAX DISEASE; URTICARIA;

EID: 11144354599     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh092     Document Type: Article

References (13)

1. Matsumura Y, Maeda H. A new concept for macro-molecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.
2. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6: 193-210.
3. Matsumura Y, Maruo K, Kimura K et al. Kinin-generating cascade in advanced cancer pts and in vitro study. Jpn J Cancer Res 1991; 82: 732-741.
4. Allen TM, Hansen C, Martin F et al. Liposome containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochem Biophys Acta 1991; 1066: 29-36.
5. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. FEBS Lett 1990; 268: 235-237.
6. Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-992.
7. Gabizon A, Chemla M, Tzemach D et al. Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 1996; 3: 391-398.
8. Unezaki S, Maruyama K, Ishida O et al. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic polyethylene glycol. Int J Pharm 1995; 126: 41-48.
9. Hosokawa S, Tagawa T, Niki H et al. Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br J Cancer 2003; 89: 1545-1551.
10. Simon R, Freidlin, B, Rubinstein L et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997; 89: 1138-1147.
11. Tokuda Y, Watanabe T, Omuro Y et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in pts with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 1999; 81: 1419-1425.
12. Goren D, Horowitz AT, Zalipsky S et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies. Br J Cancer 1996; 74: 1749-1756.
13. Maruyama K, Takahashi N, Tagawa T et al. Immunoliposomes bearing poloethylene glycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997; 413: 177-180.